Adiponectin and the cardiovascular system: From risk to disease

Internal and Emergency Medicine

Volumn 2, Issue 3, 2007, Pages 165-176

  Tarquini, R ^a,b   Lazzeri, C ^a   Laffi, G ^a   Gensini, G F ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Adipokynes; Adiponectin; Cardiovascular risk; Metabolic syndrome; Visceral fat

Indexed keywords

ADENOSINE PHOSPHATE; ADIPONECTIN; FATTY ACID; GLUCOSE;

CARDIOVASCULAR DISEASE; HUMAN; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR;

ADENOSINE MONOPHOSPHATE; ADIPONECTIN; CARDIOVASCULAR DISEASES; FATTY ACIDS; GLUCOSE; HUMANS; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; RISK FACTORS;

EID: 35948941155     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-007-0027-9     Document Type: Review

References (100)

1. Matsuzawa Y (2005) White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 19:637-647
2. Zimmet P, Magliano D, Matsuzawa Y et al (2005) The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295-300
3. Maeda K, Okubo K, Shimomura I et al (1997) Analysis of an expression profile of genes in the human adipose tissue. Gene 190:227-235
4. Maeda K, Okubo K, Shimomura I et al (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289
5. Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935
6. Ouchi N, Kihara S, Arita Y et al (2001) Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063
7. Arita Y, Kihara S, Ouchi N et al (2002) Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893-2898
8. Cruz M, Garcia-Macedo R, Garcia-Valerio Y et al (2004) Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 27:1451-1453
9. Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599
10. Baratta R, Amato S, Degano C et al (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89:2665-2671
11. Kim OY, Koh SJ, Jang Y et al (2006) Plasma adiponectin is related to other cardiovascular risk factors in nondiabetic Korean men with CAD, independent of adiposity and cigarette smoking: cross-sectional analysis. Clin Chim Acta 370:63-71
12. Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 892:146-154
13. Furuhashi M, Ura N, Higashiura K et al (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76-81
14. Ouchi N, Kihara S, Arita Y et al (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476
15. Okamoto Y, Kihara S, Ouchi N et al (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770
16. Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946
17. Scherer PE, Williams S, Fogliano M et al (1995) A novel serum protein similar to C1q produced exclusively in adipocytes. J Biol Chem 270:26746-26749
18. Pajvani UB, Du X, Combs TP et al (2003) Structure-function studies of the adipocyte-secreted hormone Acrp3/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085
19. Stefan N, Vozarova B, Funahashi T et al (2002) Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51:1884-1888
20. Okamoto Y, Arita Y, Nishida M et al (2000) An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32:47-50
21. Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769
22. Civitarese AE, Jenkinson CP, Richardson D et al (2004) Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 47:816-822
23. Okamoto Y, Kihara S, Funahashi T et al (2006) Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 110:267-278
24. Takahashi T, Saegusa S, Sumino H et al (2005) Adiponectin, T-cadherin and tumour necrosis factor-alpha in damaged cardiomyocytes from autopsy specimens. J Int Med Res 33:236-244
25. Shibata R, Sato K, Pimentel DR et al (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096-1103
26. Punthakee Z, Delvin EE, O'Loughlin J et al (2006) Adiponectin, adiposity and insulin resistance in children and adolescents. J Clin Endocrinol Metab 91:2119-2125
27. Chan DC, Watts GF, Ng TW et al (2006) Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab 8:698-702
28. Lee S, Bacha F, Gungor N, Arslanian SA (2006) Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. Diabetes Care 29:51-56
29. Nishizawa H, Shimomura I, Kishida K et al (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734-2741
30. Cnop M, Havel PJ, Utzschneider KM et al (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459-469
31. Matsuda M, Shimomura I, Sata M et al (2002) Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487-37491
32. Chen H, Montagnani M, Funahashi T et al (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021-45026
33. Mallamaci F, Zoccali C, Cuzzola F et al (2002) Adiponectin in essential hypertension. J Nephrol 15:507-511
34. Adamczak M, Wiecek A, Funahashi T et al (2003) Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16:72-75
35. Kazumi T, Kawaguchi A, Sakai K et al (2002) Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971-976
36. Iwashima Y, Katsuya T, Ishikawa K et al (2004) Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318-1323
37. Ouchi N, Ohishi M, Kihara S et al (2003) Association of hypoadiponectemia. Hypertension 42:231-234
38. Vita JA, Keaney JF Jr (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106:640-642
39. Fasshauer M, Klein J, Neumann S et al (2001) Adiponectin gene expression is inhibited by beta-adrenergic stimulation via proteins kinase A in 3T3-L1 adipocytes. FEBS Lett 507:142-146
40. Reaven GM (1988) Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607
41. Murakami H, Ura N, Furuhashi M et al (2003) Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 26:705-710
42. Kondo H, Shimomura I, Matsukawa Y et al (2002) Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51:2325-2328
43. Ohashi K, Ouchi N, Kihara S et al (2004) Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43:1195-1200
44. Hara K, Boutin P, Mori Y et al (2002) Genetic variation in the gene encoding adiponectin is associated with an increased risk type 2 diabetes in Japanese population. Diabetes 51:536-640
45. Yilmaz MI, Sonmez A, Kilic S et al (2005) The association of plasma adiponectin levels with hypertensive retinopathy. Eur J Endocrinol 152:233-240
46. Tsioufis C, Dimitriadis K, Chatzis D et al (2005) Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 96:946-951
47. Hong SJ, Park CG, Seo HS et al (2004) Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 13:236-242
48. Spranger J, Kroke A, Mohlig M et al (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226-228
49. Schulze MB, Shai I, Rimm EB et al (2005) Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54:534-539
50. Furuhashi M, Ura N, Moniwa N et al (2004) Possible impairment of transcardiac utilization of adiponectin in patients with type 2 diabetes. Diabetes Care 27:2217-2221
51. Maruyoshi H, Kojima S, Otsuka F et al (2005) Hypoadiponectinemia is associated with coronary artery spasm in men. Circ J 69:1154-1156
52. Kojima S, Funahashi T, Sakamoto T et al (2003) The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89:667
53. Nystrom T, Nygren A, Sjoholm A (2005) Persistent endothelial dysfunction is related to elevated C-reactive protein (CRP) levels in Type II diabetic patients after acute myocardial infarction. Clin Sci (Lond) 108:121-128
54. Choi KM, Lee KW, Kim SG et al (2005) Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab 90:175-180
55. Nakamura Y, Shimada K, Fukuda D et al (2004) Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 90:528-533
56. Kumada M, Kihara S, Sumitsuji S et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89
57. Lawlor DA, Davey Smith G, Ebrahim S et al (2005) Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90:5677-5683
58. Xu A, Chan KW, Hoo RL et al (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073-18080
59. Lawlor DA, Ebrahim S, Whincup P et al (2004) Sex differences in body fat distribution and carotid intima media thickness: cross sectional survey using data from the British regional heart study. J Epidemiol Community Health 58:700-704
60. Rothenbacher D, Brenner H, Marz W, Koenig W (2005) Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 26:1640-1646
61. von Eynatten M, Schneider JG, Humpert PM et al (2006) Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 47:2124-2126
62. Wolk R, Berger P, Lennon RJ et al (2003) Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation 108:2206-2211
63. Pischon T, Girman CJ, Hotamisligil GS et al (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737
64. George J, Patal S, Wexler D et al (2006) Circulating adiponectin levels predict outcome in patients with severe congestive heart failure. Heart DOI:10.1136/hrt.2005.083345
65. Kistorp C, Faber J, Galatius S et al (2005) Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112:1756-1762
66. Qi Y, Takahashi N, Hileman SM et al (2004) Adiponectin acts in the brain to decrease body weight. Nat Med 10:524-529
67. Yang WS, Lee WJ, Funahashi T et al (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819
68. Chamorro A (2004) Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 17[Suppl 3]:1-5
69. Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293-300
70. Soderberg S, Stegmayr B, Stenlund H et al (2004) Leptin, but not adiponectin, predicts stroke in males. J Intern Med 256:128-136
71. Chen MP, Tsai JC, Chung FM et al (2005) Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25:821-826
72. Efstathiou SP, Tsioulos DI, Tsiakou AG et al (2005) Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36:1915-1919
73. Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599
74. Spiegelman BM (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507-514
75. Marx N, Duez H, Fruchart JC, Staels B (2004) Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94:1168-1178
76. Maeda N, Takahashi M, Funahashi T et al (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099
77. Phillips SA, Ciaraldi TP, Kong AP et al (2003) Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52:667-674
78. Jung HS, Youn BS, Cho YM et al (2005) The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54:314-320
79. Kawai T, Takei I, Oguma Y et al (1999) Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102-1107
80. Chu CS, Lee KT, Lee MY et al (2006) Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 97:646-650
81. Samaha FF, Szapary PO, Iqbal N et al (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26:624-630
82. Abbasi F, Chang SA, Chu JW et al (2006) Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol 290:R139-R144
83. Kim SG, Ryu OH, Kim HY et al (2006) Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol 154:433-440
84. Rasouli N, Yao-Borengasser A, Miles LM et al (2006) Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 290:E42-E46
85. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ (2005) Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46:773-778
86. Miyazaki Y, Murakami H, Hirata A et al (1998) Effects of the angiotensin converting enzyme inhibitor temocapril on insulin sensitivity and its effects on renal sodium handling and the pressor system in essential hypertensive patients. Am J Hypertens 11:962-970
87. Lind L, Berne C, Lithell H (1995) Prevalence of insulin resistance in essential hypertension. J Hypertens 13:1457-1462
88. Koh KK, Quon MJ, Han SH et al (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687-3692
89. Agata J, Nagahara D, Kinoshita S et al (2004) Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J 68:1194-1198
90. Nowak L, Adamczak M, Wiecek A (2005) Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 18:1470-1475
91. Sonmez A, Dogru T, Tasci I et al (2006) The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia. Clin Endocrinol (Oxf) 64:567-572
92. Chu CS, Lee KT, Lee MY et al (2006) Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol 61:263-269
93. Gannage-Yared MH, Azar RR, Amm-Azar M et al (2005) Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 54:947-951
94. Chu CS, Lee KT, Lee MY et al (2006) Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 97:646-650
95. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176
96. Furuhashi M, Ura N, Murakami H et al (2002) Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle. J Endocrinol 174:321-329
97. Ohashi K, Kihara S, Ouchi N et al (2006) Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47:1108-1116
98. Gavrila A, Peng CK, Chan JL et al (2003) Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 88:2838-2843
99. Shea SA, Hilton MF, Orlova C et al (2005) Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 90:2537-2544
100. Monzavi R, Dreimane D, Geffner ME et al (2006) Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics 117:e1111-e1118